High cellular prion protein expression in cholangiocarcinoma: A marker for early postoperative recurrence and unfavorable prognosis

Table 1 Patient and tumor characteristics of the study, n (%)

Characteristics	Category	Subgroup (based on immunostaining)		Total (n = 76)	P value
		Low PrPC (n = 38)	High PrPC (n = 38)
Age (years), mean ± SD		66.7 ± 9.5	66.8 ± 9.8	66.7 ± 9.6	0.953
Male		22 (57.9)	27 (71.1)	49 (64.5)	0.338
BMI (kg/m2), mean ± SD		24.4 ± 2.9	23.4 ± 2.7	23.9 ± 2.8	0.139
Location	Hilar CCA	22 (57.9)	15 (39.5)	37 (48.7)	0.169
	Intrahepatic CCA	16 (42.1)	23 (60.5)	39 (51.3)
Tumor size (cm), mean ± SD		4.1 ± 1.9	5.3 ± 3.5	4.7 ± 2.8	0.056
Positive LN		17 (44.7)	17 (44.7)	34 (44.7)	1.000
TNM stage	I	6 (15.8)	5 (13.2)	11 (14.5)	0.890
	II	9 (23.7)	8 (21.1)	17 (22.4)
	III	23 (60.5)	25 (65.8)	48 (63.2)
Resection margin	R0	27 (71.1)	21 (55.3)	48 (63.2)	0.262
	R1	11 (28.9)	16 (42.1)	27 (35.5)
	R2	0 (0.0)	1 (2.6)	1 (1.3)
Differentiation	WD	8 (21.1)	12 (31.6)	20 (26.3)	0.177
	MD	25 (65.8)	25 (65.8)	50 (65.8)
	PD	5 (13.2)	1 (2.6)	6 (7.9)
Laboratory tests	CEA (ng/dL)	5.6 ± 4.4	11.1 ± 31.0	8.1 ± 21.0	0.406
	CA19-9 (U/mL)	813.7 ± 2038.1	1115.9 ± 2461.6	957.8 ± 2237.2	0.591

PrP^C: Cellular prion protein; BMI: Body mass index; LN: Lymph node; TNM: Tumor-node-metastasis; CCA: Cholangiocarcinoma; R0: No cancer cells seen microscopically at the primary tumor site; R1: Cancer cells present microscopically at the primary tumor site; R2: Macroscopic residual tumor at primary cancer site or regional lymph nodes; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; WD: Well-differentiated; MD: Moderately differentiated; PD: Poorly differentiated.